Boston - Early-stage breast cancer patients who receive a more intensive course of radiation to their whole breast over three weeks is as effective as the standard, less intensive five-week whole breast radiation and offers patients more convenience at a lower cost, thereby providing a better quality of life, according to a randomized, long-term study presented September 22, 2008, in the plenary session at the American Society for Therapeutic Radiology and Oncology's 50th Annual Meeting in Boston.
The cost of this shorter treatment, called accelerated hypofractionated whole breast irradiation, is two-thirds of the cost of the standard whole breast radiation. It is also less expensive then other new approaches such as partial breast irradiation.
"There has been renewed interest in hypofractioned whole breast irradiation, due to the potential radiation advantages, patient convenience, quality of life and lower costs. However, long-term effects were a potential concern," Timothy Whelan, M.D., lead author of the study and a radiation oncologist at the Juravinski Cancer Centre at McMaster University in Hamilton, Ontario, Canada, said. "We were surprised that the risk of local recurrence and side effects for women treated with accelerated whole breast irradiation was so low even at 12 years. Our study shows that this treatment should be offered to select women treated with early-stage breast cancer."
Many women with early-stage breast cancer are able to undergo breast conserving therapy to keep their breast after treatment. Typically, this means they first have surgery to remove the cancer (called a lumpectomy) followed by a course of radiation therapy to kill any cancer cells that may remain. The standard whole breast radiation therapy treatment takes approximately 15 minutes every day, Monday through Friday, for five weeks.
Between April 1993 and September 1996, researchers randomly assigned 1,234 women to be treated with either accelerated whole breast irradiation or standard whole breast irradiation. These women were followed for 12 years to determine if accelerated whole breast radiation was as effective as the standard treatment. At 10 years after treatment, cancer returned locally in 6.2 percent of patients treated with the accelerated radiation therapy, compared to 6.7 percent for those patients treated with standard therapy. Both groups of patients also had a good or excellent cosmetic outcome from the radiation treatments.
"This shorter treatment may not be for everyone, however, I would encourage women whose breast cancer is caught early to talk to their oncologist to see if they are a good candidate for this shorter therapy," Dr. Whelan added.
For more information on radiation therapy for breast cancer, visit www.rtanswers.org.
The abstract, "Long-Term Results of a Randomized Trial of Accelerated Hypofractionated Whole Breast Irradiation Following Breast Conserving Surgery in Women with Node-negative Breast Cancer," will be presented at the plenary session at 2:00 p.m. on Monday, September 22, 2008. To speak to the lead author of the study, Timothy Whelan, M.D., please call Beth Bukata or Nicole Napoli September 21-24, 2008, in the ASTRO Press Room at the Boston Convention and Exhibition Center at 617-954-3377 or 617-954-3378. You may also e-mail them at firstname.lastname@example.org or email@example.com.